Evaluation of the risk of occupational exposure to antineoplastic drugs in healthcare sector: part II – the application of the FMECA method to compare manual vs automated preparation

1. Institute for Safe Medication Practices (ISIMP). ISMP list of high-alert medications in acute care settings [displayed 7 March 2024]. Available at https://www.ismp.org/sites/default/files/attachments/2018-08/highAlert2018-Acute-Final.pdf Institute for Safe Medication Practices (ISIMP) ISMP list of high-alert medications in acute care settings [displayed 7 March 2024] Available at https://www.ismp.org/sites/default/files/attachments/2018-08/highAlert2018-Acute-Final.pdf Search in Google Scholar

2. Carrez L, Falaschi L, Cingria L, Sadeghipour F, Bouchoud L, Bonnabry P. [Organisation et sécurisation du circuit des chimiothérapies: Exemple de la pharmacie des Hôpitaux Universitaires de Genève, in French]. Pharmactuel 2014;47:119–24. CarrezL FalaschiL CingriaL SadeghipourF BouchoudL BonnabryP [Organisation et sécurisation du circuit des chimiothérapies: Exemple de la pharmacie des Hôpitaux Universitaires de Genève, in French] Pharmactuel 2014 47 119 24 Search in Google Scholar

3. Palma E, Bufarini C. Robotized compounding of oncology drugs in a hospital pharmacy. Int J Pharm Compd 2014;18:358–64. PMID: 25577883 PalmaE BufariniC Robotized compounding of oncology drugs in a hospital pharmacy Int J Pharm Compd 2014 18 358 64 25577883 Search in Google Scholar

4. Hon C-Y, Teschke K, Chua P, Venners S, Nakashima L. Occupational exposure to antineoplastic drugs: identification of job categories potentially exposed throughout the hospital medication system. Saf Health Work 2011;2(3):273–81. doi: 10.5491/SHAW.2011.2.3.273 HonC-Y TeschkeK ChuaP VennersS NakashimaL Occupational exposure to antineoplastic drugs: identification of job categories potentially exposed throughout the hospital medication system Saf Health Work 2011 2 3 273 81 10.5491/SHAW.2011.2.3.273 Open DOISearch in Google Scholar

5. Ndaw S, Remy A. Occupational exposure to antineoplastic drugs in twelve French health care setting: biological monitoring and surface contamination. Int J Environ Res Public Health 2023;20(6):4952. doi: 10.3390/ijerph20064952 NdawS RemyA Occupational exposure to antineoplastic drugs in twelve French health care setting: biological monitoring and surface contamination Int J Environ Res Public Health 2023 20 6 4952 10.3390/ijerph20064952 Open DOISearch in Google Scholar

6. Mucci N, Dugheri S, Farioli A, Garzaro G, Rapisarda V, Campagna M, Bonari A, Arcangeli G. Occupational exposure to antineoplastic drugs in hospital environments: potential risk associated with contact with cyclophosphamide- and ifosfamide-contaminated surfaces. Med Pr 2020;71:519–29. doi: 10.13075/mp.5893.00931 MucciN DugheriS FarioliA GarzaroG RapisardaV CampagnaM BonariA ArcangeliG Occupational exposure to antineoplastic drugs in hospital environments: potential risk associated with contact with cyclophosphamide- and ifosfamide-contaminated surfaces Med Pr 2020 71 519 29 10.13075/mp.5893.00931 Open DOISearch in Google Scholar

7. Dugheri S, Mucci N, Mini E, Cappelli G, Bucaletti E, Squillaci D, Trevisani L, Arcangeli G. An update on permeation of protective medical gloves by antineoplastic drugs. Sigurnost 2022;64:341–57. doi: 10.31306/s.64.4.2 DugheriS MucciN MiniE CappelliG BucalettiE SquillaciD TrevisaniL ArcangeliG An update on permeation of protective medical gloves by antineoplastic drugs Sigurnost 2022 64 341 57 10.31306/s.64.4.2 Open DOISearch in Google Scholar

8. Korczowska E, Jankowiak-Gracz H, Crul M, Tuerk J, Arnold D, Meier K. Surface contamination with cytotoxic drugs in european hospital wards. Eur J Hosp Pharm 2020;27(Suppl 1):A41. KorczowskaE Jankowiak-GraczH CrulM TuerkJ ArnoldD MeierK Surface contamination with cytotoxic drugs in european hospital wards Eur J Hosp Pharm 2020 27 Suppl 1 A41 Search in Google Scholar

9. Falck K, Gröhn P, Sorsa M, Vainio H, Heinonen E, Holsti LR. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979;313:1250–1. doi: 10.1016/s0140-6736(79)91939-1 FalckK GröhnP SorsaM VainioH HeinonenE HolstiLR Mutagenicity in urine of nurses handling cytostatic drugs Lancet 1979 313 1250 1 10.1016/s0140-6736(79)91939-1 Open DOISearch in Google Scholar

10. Nurse24.it. Manipolazione farmaci antiblastici: Uno sguardo al futuro [Handling antineoplastic pharmaceuticals: a look at the future, in Italian] [displayed 20 August 2023]. Available at https://www.nurse24.it/infermiere/farmaci/antiblastici-manipolazione-rischi-infermiere.html Nurse24.it Manipolazione farmaci antiblastici: Uno sguardo al futuro [Handling antineoplastic pharmaceuticals: a look at the future, in Italian] [displayed 20 August 2023] Available at https://www.nurse24.it/infermiere/farmaci/antiblastici-manipolazione-rischi-infermiere.html Search in Google Scholar

11. AboutPharma. Preparazione di farmaci antiblastici, quadro ancora frammentato in Italia: “serve fare rete” [Preparation of antineoplastic pharmaceuticals, still a fragmented picture in Italy: needs creating a net, in Italian] [displayed 20 August 2023]. Available at https://www.aboutpharma.com/business-e-mercato/preparazione-farmaciantiblastici-quadro-ancora-frammentato-italia-serve-rete/ AboutPharma Preparazione di farmaci antiblastici, quadro ancora frammentato in Italia: “serve fare rete” [Preparation of antineoplastic pharmaceuticals, still a fragmented picture in Italy: needs creating a net, in Italian] [displayed 20 August 2023]. Available at https://www.aboutpharma.com/business-e-mercato/preparazione-farmaciantiblastici-quadro-ancora-frammentato-italia-serve-rete/ Search in Google Scholar

12. Adade CA, Benabbes M, Belahcen MJ, Rahali Y. Centralization impact and cost-saving study in a Moroccan hospital’s centralized unit of chemotherapy preparation. J Oncol Pharm Pract 2020;26:1630–6. doi: 10.1177/1078155220901336 AdadeCA BenabbesM BelahcenMJ RahaliY Centralization impact and cost-saving study in a Moroccan hospital’s centralized unit of chemotherapy preparation J Oncol Pharm Pract 2020 26 1630 6 10.1177/1078155220901336 Open DOISearch in Google Scholar

13. Notiziario Chimico Farmaceutico. [UFA: Unità Farmaci Antiblastici, in Italian] [displayed 20 August 2023]. Available at https://www.notiziariochimicofarmaceutico.it/2017/09/04/migliorare-la-gestionedelle-ufa/ Notiziario Chimico Farmaceutico [UFA: Unità Farmaci Antiblastici, in Italian] [displayed 20 August 2023]. Available at https://www.notiziariochimicofarmaceutico.it/2017/09/04/migliorare-la-gestionedelle-ufa/ Search in Google Scholar

14. HTA Focus. Pills of Clinical Governance 2017;4(2):55–120 [displayed 20 August 2023]. Available at https://www.htafocus.it/pdfvol4-n2-2017 HTA Focus Pills of Clinical Governance 2017 4 2 55 120 [displayed 20 August 2023]. Available at https://www.htafocus.it/pdfvol4-n2-2017 Search in Google Scholar

15. Farmacia Ospedaliera. [Rapporto tra numero di preparati allestiti al giorno, personale necessario e costo per preparato nelle UFA, in Italian] [displayed 20 August 2023]. Available at https://www.farmaciaospedaliera.it/rapporto-tra-numero-di-preparati-allestiti-algiorno-personale-necessario-e-costo-per-preparato-nelle-ufa/ Farmacia Ospedaliera [Rapporto tra numero di preparati allestiti al giorno, personale necessario e costo per preparato nelle UFA, in Italian] [displayed 20 August 2023]. Available at https://www.farmaciaospedaliera.it/rapporto-tra-numero-di-preparati-allestiti-algiorno-personale-necessario-e-costo-per-preparato-nelle-ufa/ Search in Google Scholar

16. Cote DD, Torchia MG. Robotic system for i.v. antineoplastic drug preparation: description and preliminary evaluation under simulated conditions. Am J Hosp Pharm 1989;46:2286–93. PMID: 2589345 CoteDD TorchiaMG Robotic system for i.v. antineoplastic drug preparation: description and preliminary evaluation under simulated conditions Am J Hosp Pharm 1989 46 2286 93 2589345 Search in Google Scholar

17. Fox BI, Felkey BG. Automated intravenous preparation: robots for the pharmacy. Hosp Pharm 2009;44:255–7. doi: 10.1310/hpj4403-255 FoxBI FelkeyBG Automated intravenous preparation: robots for the pharmacy Hosp Pharm 2009 44 255 7 10.1310/hpj4403-255 Open DOISearch in Google Scholar

18. Schoening T, Artes A, Ehmann M, Mertens M, Ober M, Hoppe-Tichy T. Semiautomated aseptic preparation of patient-individual antineoplastic intravenous solutions: first experiences in a German hospital pharmacy. Eur J Hosp Pharm 2016;23:44–9. doi: 10.1136/ejhpharm-2015-000655 SchoeningT ArtesA EhmannM MertensM OberM Hoppe-TichyT Semiautomated aseptic preparation of patient-individual antineoplastic intravenous solutions: first experiences in a German hospital pharmacy Eur J Hosp Pharm 2016 23 44 9 10.1136/ejhpharm-2015-000655 Open DOISearch in Google Scholar

19. Schierl R, Masini C, Groeneveld S, Fischer E, Böhlandt A, Rosini V, Paolucci D. Environmental contamination by cyclophosphamide preparation: Comparison of conventional manual production in biological safety cabinet and robot-assisted production by APOTECAchemo. J Oncol Pharm Pract 2014;22:37–45. doi: 10.1177/1078155214551316 SchierlR MasiniC GroeneveldS FischerE BöhlandtA RosiniV PaolucciD Environmental contamination by cyclophosphamide preparation: Comparison of conventional manual production in biological safety cabinet and robot-assisted production by APOTECAchemo J Oncol Pharm Pract 2014 22 37 45 10.1177/1078155214551316 Open DOISearch in Google Scholar

20. Carrez L, Martin V, Verrey A, Furrer P, Bouchoud L, Falaschi L, Bonnabry P. Qualification and performance evaluation of an automated system for compounding injectable cytotoxic drugs. Pharm Technol Hosp Pharm 2018;3:165–75. doi: 10.1515/pthp-2018-0012 CarrezL MartinV VerreyA FurrerP BouchoudL FalaschiL BonnabryP Qualification and performance evaluation of an automated system for compounding injectable cytotoxic drugs Pharm Technol Hosp Pharm 2018 3 165 75 10.1515/pthp-2018-0012 Open DOISearch in Google Scholar

21. Yaniv AW, Knoer SJ. Implementation of an i.v.-compounding robot in a hospital-based cancer center pharmacy. Am J Health Syst Pharm 2013;70:2030–7. doi: 10.2146/ajhp120649 YanivAW KnoerSJ Implementation of an i.v.-compounding robot in a hospital-based cancer center pharmacy Am J Health Syst Pharm 2013 70 2030 7 10.2146/ajhp120649 Open DOISearch in Google Scholar

22. Masini C, Nanni O, Antaridi S, Gallegati D, Marri M, Paolucci D, Minguzzi M, Altini M. Automated preparation of chemotherapy: quality improvement and economic sustainability. Am J Health Syst Pharm 2014;71:579–85. doi: 10.2146/ajhp130489 MasiniC NanniO AntaridiS GallegatiD MarriM PaolucciD MinguzziM AltiniM Automated preparation of chemotherapy: quality improvement and economic sustainability Am J Health Syst Pharm 2014 71 579 85 10.2146/ajhp130489 Open DOISearch in Google Scholar

23. Nurgat Z, Faris D, Mominah M, Vibar A, Al-Jazairi A, Ewing S, Ashour M, Qaisi SK, Balhareth S, Al-Jedai A. A three-year study of a first-generation chemotherapy-compounding robot. Am J Health Syst Pharm 2015;72:1036–45. doi: 10.2146/ajhp140256 NurgatZ FarisD MominahM VibarA Al-JazairiA EwingS AshourM QaisiSK BalharethS Al-JedaiA A three-year study of a first-generation chemotherapy-compounding robot Am J Health Syst Pharm 2015 72 1036 45 10.2146/ajhp140256 Open DOISearch in Google Scholar

24. Foglia E, Asperti F, Bellavia D, Schettini F, Cecchi A, Morassutto C. Unità Farmaci Antitumorali: modelli organizzativi e logistici a confronto. Uno studio condotto in Friuli-Venezia Giulia ha analizzato diversi scenari per definire il setting organizzativo e logistico maggiormente efficiente per la preparazione di agenti chemioterapici [Antitumour Drug Union: facing organisational and logistical models, in Italian] [displayed 20 August 2023]. Available at https://trendsanita.it/unita-farmaci-antitumorali-organizzazione-logistica/ FogliaE AspertiF BellaviaD SchettiniF CecchiA MorassuttoC Unità Farmaci Antitumorali: modelli organizzativi e logistici a confronto. Uno studio condotto in Friuli-Venezia Giulia ha analizzato diversi scenari per definire il setting organizzativo e logistico maggiormente efficiente per la preparazione di agenti chemioterapici [Antitumour Drug Union: facing organisational and logistical models, in Italian] [displayed 20 August 2023]. Available at https://trendsanita.it/unita-farmaci-antitumorali-organizzazione-logistica/ Search in Google Scholar

25. American Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health Syst Pharm 2006;63:1172–93. American Society of Health-System Pharmacists ASHP guidelines on handling hazardous drugs Am J Health Syst Pharm 2006 63 1172 93 Search in Google Scholar

26. International Society of Oncology Pharmacy Practicioners Standards Committee. ISOPP standards of practice. Safe handling of cytotoxics. J Oncol Pharm Pract 2007;13(Suppl):1–81. doi: 10.1177/1078155207082350 International Society of Oncology Pharmacy Practicioners Standards Committee ISOPP standards of practice. Safe handling of cytotoxics J Oncol Pharm Pract 2007 13 Suppl 1 81 10.1177/1078155207082350 Open DOISearch in Google Scholar

27. European Agency for Safety and Health at Work. Guidance for the safe management of hazardous medicinal products at work [displayed 20 August 2023]. Available at https://osha.europa.eu/en/publications/guidance-safe-management-hazardous-medicinal-products-work European Agency for Safety and Health at Work Guidance for the safe management of hazardous medicinal products at work [displayed 20 August 2023]. Available at https://osha.europa.eu/en/publications/guidance-safe-management-hazardous-medicinal-products-work Search in Google Scholar

28. Yeh TM, Chen LY. Fuzzy-based risk priority number in FMEA for semiconductor wafer processes. Int J Prod Res 2014;52:539–49. doi: 10.1080/00207543.2013.837984 YehTM ChenLY Fuzzy-based risk priority number in FMEA for semiconductor wafer processes Int J Prod Res 2014 52 539 49 10.1080/00207543.2013.837984 Open DOISearch in Google Scholar

29. Jiang Y, Jiang H, Ding S, Liu Q. Application of failure mode and effects analysis in a clinical chemistry laboratory. Clin Chim Acta Int J Clin Chem 2015;448:80–5. doi: 10.1016/j.cca.2015.06.016 JiangY JiangH DingS LiuQ Application of failure mode and effects analysis in a clinical chemistry laboratory Clin Chim Acta Int J Clin Chem 2015 448 80 5 10.1016/j.cca.2015.06.016 Open DOISearch in Google Scholar

30. Lago P, Bizzarri G, Scalzotto F, Parpaiola A, Amigoni A, Putoto G, Perilongo G. Use of FMEA analysis to reduce risk of errors in prescribing and administering drugs in paediatric wards: a quality improvement report. BMJ Open 2012;2:e001249. doi:10.1136/bmjopen-2012-001249 LagoP BizzarriG ScalzottoF ParpaiolaA AmigoniA PutotoG PerilongoG Use of FMEA analysis to reduce risk of errors in prescribing and administering drugs in paediatric wards: a quality improvement report BMJ Open 2012 2 e001249 10.1136/bmjopen-2012-001249 Open DOISearch in Google Scholar

31. Cherif Chefchaouni A, Boudina Y, Chennaq M, Belahcen MJ, Rahali Y. Contribution of an anticancer drug compounding robot in reducing the risks of manual preparation in a hospital pharmacy unit specialized in oncology. J Oncol Pharm Pract 2023;29:1334–42. doi: 10.1177/10781552221118846 Cherif ChefchaouniA BoudinaY ChennaqM BelahcenMJ RahaliY Contribution of an anticancer drug compounding robot in reducing the risks of manual preparation in a hospital pharmacy unit specialized in oncology J Oncol Pharm Pract 2023 29 1334 42 10.1177/10781552221118846 Open DOISearch in Google Scholar

32. Bhirich N, Chefchaouni AC, Medkouri SE, Shytry O, Belahcen MJ, Rahali Y. Risk assessment of personnel exposure in a central cytotoxic preparation unit using the FMECA method. J Oncol Pharm Pract 2023;29:1884–92. doi: 10.1177/10781552231153625 BhirichN ChefchaouniAC MedkouriSE ShytryO BelahcenMJ RahaliY Risk assessment of personnel exposure in a central cytotoxic preparation unit using the FMECA method J Oncol Pharm Pract 2023 29 1884 92 10.1177/10781552231153625 Open DOISearch in Google Scholar

33. Zribi K, Minh Mai Le L, Rajkumar A, Aboudagga H, Frikha M, Dietrich A, Zribi E, Safta F, Caudron E. Antineoplastic drug handling: higher risk for healthcare workers in Tunisia than in France? Biomed Environ Sci 2020;33:803–6. doi: 10.3967/bes2020.108 ZribiK Minh Mai LeL RajkumarA AboudaggaH FrikhaM DietrichA ZribiE SaftaF CaudronE Antineoplastic drug handling: higher risk for healthcare workers in Tunisia than in France? Biomed Environ Sci 2020 33 803 6 10.3967/bes2020.108 Open DOISearch in Google Scholar

34. Dugheri S, Squillaci D, Cappelli G, Saccomando V, Fanfani N, Ceccarelli J, Mucci N, Arcangeli G. Evaluation of the risk of occupational exposure to antineoplastic drugs in healthcare sector: part I – medical gloves. Arh Hig Rada Toksikol 2023;74:187–97. doi: 10.2478/aiht-2023-74-3734 DugheriS SquillaciD CappelliG SaccomandoV FanfaniN CeccarelliJ MucciN ArcangeliG Evaluation of the risk of occupational exposure to antineoplastic drugs in healthcare sector: part I – medical gloves Arh Hig Rada Toksikol 2023 74 187 97 10.2478/aiht-2023-74-3734 Open DOISearch in Google Scholar

35. Gilpin WR, Powitz WR. NSF International NSF 49-2019 Informative Annex 1 (formerly Annex E) Biosafety cabinet selection, installation, use, lifespan and decommissioning [technical report 2020 NSF NSF/ANSI 49-2019]. doi: 10.13140/RG.2.2.31444.96645 GilpinWR PowitzWR NSF International NSF 49-2019 Informative Annex 1 (formerly Annex E) Biosafety cabinet selection, installation, use, lifespan and decommissioning [technical report 2020 NSF NSF/ANSI 49-2019] 10.13140/RG.2.2.31444.96645 Open DOISearch in Google Scholar

36. European Commission (EC). The rules governing medical products in the European Union volume 4 EU guidelines for good manufacturing practice for medical products for human and veterinary use [displayed 7 March 2024]. Available at: https://health.ec.europa.eu/document/download/e05af55b-38e9-42bf-8495-194bbf0b9262_en?filename=20220825_gmp-an1_en_0.pdf European Commission (EC) The rules governing medical products in the European Union volume 4 EU guidelines for good manufacturing practice for medical products for human and veterinary use [displayed 7 March 2024] Available at: https://health.ec.europa.eu/document/download/e05af55b-38e9-42bf-8495-194bbf0b9262_en?filename=20220825_gmp-an1_en_0.pdf Search in Google Scholar

37. Heloury J, Bougeon G, Deljehier T, Jourand A, Berroneau A, Crauste-Manciet S. Automation of aseptic sterile preparation: risk analysis and productivity comparison with manual process. Pharm Technol Hosp Pharm 2019;4:15–28. doi: 10.1515/pthp-2019-0001 HelouryJ BougeonG DeljehierT JourandA BerroneauA Crauste-MancietS Automation of aseptic sterile preparation: risk analysis and productivity comparison with manual process Pharm Technol Hosp Pharm 2019 4 15 28 10.1515/pthp-2019-0001 Open DOISearch in Google Scholar

38. Spivey S, Connor TH. Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system. Hosp Pharm 2003;38:135–9. doi: 10.1177/001857870303800 SpiveyS ConnorTH Determining sources of workplace contamination with antineoplastic drugs and comparing conventional IV drug preparation with a closed system Hosp Pharm 2003 38 135 9 10.1177/001857870303800 Open DOISearch in Google Scholar

39. Fleury-Souverain S, Nussbaumer S, Mattiuzzo M, Bonnabry P. Determination of the external contamination and cross-contamination by cytotoxic drugs on the surfaces of vials available on the Swiss market. J Oncol Pharm Pract 2013;20:100–11. doi: 10.1177/1078155213482683 Fleury-SouverainS NussbaumerS MattiuzzoM BonnabryP Determination of the external contamination and cross-contamination by cytotoxic drugs on the surfaces of vials available on the Swiss market J Oncol Pharm Pract 2013 20 100 11 10.1177/1078155213482683 Open DOISearch in Google Scholar

40. Silva LSE, Machado CDSB, Linden R, Antunes MV, da Silva LC, Wayhs CAY, Capp E, Ness SLR. Residual contamination in antineoplastic drug packaging. J Oncol Pharm Pract 2023;29:1862–7. doi: 10.1177/10781552231151693 SilvaLSE MachadoCDSB LindenR AntunesMV da SilvaLC WayhsCAY CappE NessSLR Residual contamination in antineoplastic drug packaging J Oncol Pharm Pract 2023 29 1862 7 10.1177/10781552231151693 Open DOISearch in Google Scholar

41. Hilliquin D, Tanguay C, Bussières JF. External contamination of commercial containers by antineoplastic agents: a literature review. Eur J Hosp Pharm 2020;27:313–4. doi: 10.1136/ejhpharm-2018-001705 HilliquinD TanguayC BussièresJF External contamination of commercial containers by antineoplastic agents: a literature review Eur J Hosp Pharm 2020 27 313 4 10.1136/ejhpharm-2018-001705 Open DOISearch in Google Scholar

42. Gilbert RE, Kozak MC, Dobish RB, Bourrier VC, Koke PM, Kukreti V, Logan HA, Easty AC, Trbovich PL. Intravenous chemotherapy compounding errors in a follow-up pan-Canadian observational study. J Oncol Pract 2018;14(5):e295-e303. doi: 10.1200/JOP.17.00007 GilbertRE KozakMC DobishRB BourrierVC KokePM KukretiV LoganHA EastyAC TrbovichPL Intravenous chemotherapy compounding errors in a follow-up pan-Canadian observational study J Oncol Pract 2018 14 5 e295 e303 10.1200/JOP.17.00007 Open DOISearch in Google Scholar

43. Cotteret C, Secretan PH, Gilles-Afchain L, Rousseau J, Vidal F, Salguero-Hernandez G, Batista J, Valverde V, Guitton J, Cisternino S, Schlatter J. External contamination of antineoplastic drug vials: an occupational risk to consider. Eur J Hosp Pharm 2022;29:284–6. doi: 10.1136/ejhpharm-2020-002440 CotteretC SecretanPH Gilles-AfchainL RousseauJ VidalF Salguero-HernandezG BatistaJ ValverdeV GuittonJ CisterninoS SchlatterJ External contamination of antineoplastic drug vials: an occupational risk to consider Eur J Hosp Pharm 2022 29 284 6 10.1136/ejhpharm-2020-002440 Open DOISearch in Google Scholar

44. Dugheri S, Mucci N, Bucaletti E, Squillaci D, Cappelli G, Trevisani L, Bonari A, Cecchi M, Mini E, Ghiori A, Tognoni D, Berti N, Alderighi F, Li Vigni N, Orlandi I, Arcangeli G. Monitoring surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs). Med Pr 2022;73:383–96. doi: 10.13075/mp.5893.01288 DugheriS MucciN BucalettiE SquillaciD CappelliG TrevisaniL BonariA CecchiM MiniE GhioriA TognoniD BertiN AlderighiF Li VigniN OrlandiI ArcangeliG Monitoring surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs) Med Pr 2022 73 383 96 10.13075/mp.5893.01288 Open DOISearch in Google Scholar

45. Shaikh H, Murhammer J, Sorenson S, Cleppe J, Amelon E, Lam F. Formulation options for cyclophosphamide. Oncology Safety 2022 [displayed 10 September 2023]. Available at https://www.pppmag.com/article/2881 ShaikhH MurhammerJ SorensonS CleppeJ AmelonE LamF Formulation options for cyclophosphamide Oncology Safety 2022 [displayed 10 September 2023]. Available at https://www.pppmag.com/article/2881 Search in Google Scholar

46. US 2022/0296617 A1. Stable liquid formulations of cyclophosphamide and processed to prepare the same, 2022 [displayed 25 September 2023]. Available at https://patents.google.com/patent/US20220296617A1/en US 2022/0296617 A1 Stable liquid formulations of cyclophosphamide and processed to prepare the same 2022 [displayed 25 September 2023]. Available at https://patents.google.com/patent/US20220296617A1/en Search in Google Scholar

47. Liston DR, Davis M. Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies. Clin Cancer Res 2017;23:3489–98. doi: 10.1158/1078-0432.CCR-16-3083 ListonDR DavisM Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies Clin Cancer Res 2017 23 3489 98 10.1158/1078-0432.CCR-16-3083 Open DOISearch in Google Scholar